Possible to use them for regenerative therapies, repairing damaged organs or tissues in the body, and treating conditions such as type I diabetes or liver disease
A new method for creating stem cells for the human liver and pancreas, which could enable both cell types to be grown in sufficient quantities for clinical use, has been developed by scientists.
Using the technique, researchers have for the first time been able to grow a pure, self-renewing population of stem cells specific to the human foregut, the upper section of the human digestive system.
These so-called “Foregut stem cells” could then be developed further to produce liver or pancreatic cells. The method significantly improves on existing techniques for cultivating this type of stem cell, and raises the possibility that, with further work, they could be grown in large numbers in bioreactors. That would make it possible to use them for regenerative therapies, repairing damaged organs or tissues in the body, and treating conditions such as type I diabetes or liver disease.
“We have developed a cell culture system which allows us to specifically isolate foregut stem cells in the lab,” Dr Nicholas Hannan, from the University of Cambridge Wellcome Trust MRC Stem Cell Institute, Department of Surgery, explained. Hannan led the study, which was carried out in the lab of Dr Ludovic Vallier.
“These cells have huge implications for regenerative medicine, because they are the precursors to the thyroid upper airways, lungs, liver, pancreas, stomach and biliary systems. We now have a system where we may be able to create all these cell types from the same starting population.”
As reported in the journal Stem Cell Reports, the method also means that researchers will be able to analyse the embryonic development of foregut cells in greater depth. “We now have a platform from which we can study the early patterning events that occur during human development to produce the intestines, liver, lungs and pancreas,” Hannan added.
The approach marks a breakthrough because it overcomes some of the problems which currently limit scientists’ abilities to grow cells associated with the liver, pancreas, and other parts of the foregut in sufficiently large numbers for clinical use.
Stem cell growth starts with human pluripotent stem cells (hPSCs). These are non-specialised biological cells with the potential to transform – or “differentiate” – into any of the three primary layers of cells from which all tissues and organs develop. Because these cells also self-renew, creating copies of themselves, they offer the potential to provide an infinite source of clinically usable cells for regenerative medicine.
Go deeper with Bing News on:
Transplant therapies
- Man who received world’s first genetically-edited pig kidney transplant has died
The Massachusetts man who was the recipient of the world’s first successful transplant of a genetically-edited pig kidney has died less than two months after the procedure. Richard Slayman, of ...
- Weymouth man who received first-of-its-kind pig kidney transplant has died
The Weymouth man who became the first person to receive a genetically edited pig kidney in March has died, Mass General Hospital says.
- Massachusetts man who received world’s first genetically-edited pig kidney transplant has died
The 62-year-old, who was living with end-stage kidney disease, received a pig kidney with 69 genomic edits less than two months ago.
- University Hospitals first in Northeast Ohio to offer outpatient stem cell therapies
The UH Seidman Cancer Center started the program a year ago and modeled it after other programs around the country that have been active for nearly a decade.
- 'World first' for double hand transplant patient
A woman who had a double hand transplant has undergone pioneering NHS treatment to prevent her body rejecting them. Tanya Shepherd, from Hull, became the UK’s first female recipient of two replacement ...
Go deeper with Google Headlines on:
Transplant therapies
[google_news title=”” keyword=”Transplant therapies” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Regenerative medicine
- Regenerative medicine effort generates interest in Manchester growth
One company in Manchester's Millyard is working on a retinal patch to help cure macular degeneration affecting people's vision. Another Millyard firm is developing a tissue graft that will make it ...
- Organogenesis Shares Jump After Narrower 1Q Loss, Higher Revenue
By Zaeem Shoaib Organogenesis Holdings shares rose after the company reported a narrower loss for the first quarter along with higher revenue. Shares were ...
- ARMI project secures $100 million from Department of Defense
The Department of Defense has committed $100 million over the next 10 years to the Advanced Regenerative Manufacturing Institute (ARMI), the regional effort headquartered in the Manchester Millyard to ...
- Organogenesis Holdings Inc. Reports First Quarter 2024 Financial Results
First Quarter 2024 Financial Results Summary: Net revenue from Advanced Wound Care products of $103.9 million, an increase of 3% from the first quarter of 2023. Net revenue from Surgical & Sports ...
- DoD gives ARMI another $100M, much of it for workforce development
Inventor Dean Kamen spilled the news about getting a $100 million federal grant he hopes will help make Manchester a major hub for regenerative medicine.
Go deeper with Google Headlines on:
Regenerative medicine
[google_news title=”” keyword=”regenerative medicine” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]